Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Stanley B. CohenDepartment of Internal Medicine, Metroplex Clinical Research Center, Dallas, TX, USACorrespondence[email protected] [email protected]
View further author information

Niklas CzelothBioscience, Boehringer Ingelheim, Ingelheim, GermanyView further author information

Eric LeeInland Rheumatology, Upland, CA, USAView further author information

Piotr A. KlimiukDepartment of Rheumatology and Internal Diseases, Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, PolandView further author information

Nuala PeterMedical, Boehringer Ingelheim, Biberach, GermanyView further author information

Girish JayadevaBioscience, Boehringer Ingelheim, Ingelheim, GermanyView further author information

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Supplementary_Information.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

Supplementary_Information.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date